Terminal complement inhibition and control of hemolysis in patients with paroxysmal nocturnal hemoglobinuria who switched from high-dose eculizumab to ravulizumab: a phase IV, single-arm clinical trial
Haematologica. 2024 Nov 28.
doi: 10.3324/haematol.2024.285553.
Online ahead of print.
1 St James's University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds. m.griffin@nhs.net.
2 King's College Hospital, National Institute for Health and Care Research (NIHR) Wellcome Trust King's Clinical Research Facility, London.
3 St James's University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds.
4 Alexion, AstraZeneca Rare Disease, Boston, MA.
5 King's College Hospital, National Institute for Health and Care Research (NIHR) Wellcome Trust King's Clinical Research Facility, London, UK; King's College London, London.